KOREA PHARMA Co., Ltd.

A032300

KR7032300006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
19,240 ^KRW	-0.31%		+2.72%	-18.65%

2023	Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd.	CI
2023	KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd.	CI

KOREA PHARMA Co., Ltd. has completed an IPO in the amount of KRW 29.187 billion.

August 04, 2020 at 12:00 am EDT

KOREA PHARMA Co., Ltd. has completed an IPO in the amount of KRW 29.187 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,243,000 PriceRange: KRW 9000 Discount Per Security: KRW 270 Transaction Features: ESOP Related Offering

Latest news about KOREA PHARMA Co., Ltd.

Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd.	Nov. 29	CI
KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd.	Nov. 27	CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. and others	Nov. 23	CI
Astrogen Co.,Ltd. announced that it expects to receive KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd.	Nov. 13	CI
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) dropped from S&P Global BMI Index	23-09-18	CI
KOREA PHARMA Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
KOREA PHARMA Co., Ltd. announced that it has received KRW 50 billion in funding	21-10-25	CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 50 billion in funding	21-10-21	CI
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) added to S&P Global BMI Index	21-09-20	CI
KOREA PHARMA Co., Ltd. has completed an IPO in the amount of KRW 29.187 billion.	20-08-04	CI
KOREA PHARMA Co., Ltd. has filed an IPO.	20-04-13	CI

Chart KOREA PHARMA Co., Ltd.

Duration

Period

More charts

Company Profile

Korea Pharma Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medicinal products. The Company's main products include digestive system solvents, antidepressants, blood circulation agents, antidementia drugs, schizophrenia medicines and others.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOREA PHARMA CO., LTD.	-18.65%	155M
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals